睿知中国医院研究地图
候选清单

正在招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07175220,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Patients with locally advanced unresectable or metastatic non-small cell lung cancer diagnosed by pathology

    入选标准第 2 条

  3. AE caused by previous anti-tumor treatment has not recovered to CTCAE v5.0 level evaluation ≤ 1

    排除标准第 17 条

  4. ECOG score is 0 or 1

    入选标准第 3 条

  5. Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.

    排除标准第 19 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07175220,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age range of 18-75 years old (including both ends), gender not limited;
  2. Patients with locally advanced unresectable or metastatic non-small cell lung cancer diagnosed by pathology
  3. ECOG score is 0 or 1
  4. Expected survival period ≥ 12 weeks
  5. Has a good level of organ function
  6. Patients voluntarily joined the study and signed informed consent

排除标准:Exclusion Criteria:

  1. Having difficulty swallowing or malabsorption syndrome or any other uncontrolled gastrointestinal disease (such as nausea, diarrhea, or vomiting), having undergone gastrectomy or gastric banding surgery, etc
  2. Symptomatic or active central nervous system tumor metastasis
  3. Previously or simultaneously suffering from other malignant tumors
  4. Spinal cord compression that cannot be cured by surgery and/or radiotherapy
  5. Accompanied by uncontrolled tumor related pain
  6. Plan to receive any other anti-tumor treatment during this trial period
  7. Receive other anti-tumor treatments within 4 weeks before the first medication
  8. Having undergone major surgeries other than diagnosis or biopsy within 28 days prior to the first administration
  9. Currently participating in other clinical studies or taking medication for the first time less than 4 weeks after the end of the previous clinical study
  10. Moderate to severe pleural effusion with clinical symptoms
  11. Individuals with active pulmonary tuberculosis infection within one year prior to the first use of medication
  12. Subjects who have experienced severe infections within 30 days prior to their first medication use
  13. Administer attenuated live vaccine within 30 days before the first use of medication.
  14. History of immunodeficiency
  15. Suffering from poorly controlled or severe cardiovascular and cerebrovascular diseases
  16. History of interstitial pneumonia/non infectious pneumonia requiring hormone therapy in the past
  17. AE caused by previous anti-tumor treatment has not recovered to CTCAE v5.0 level evaluation ≤ 1
  18. Untreated active hepatitis
  19. Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.
  20. There are other serious physical or mental illnesses or laboratory abnormalities present

引自 ClinicalTrials.gov, NCT07175220, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07175220,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07175220